The complete DNA sequence of the human polyomavirus AS virus (ASV) is presented. Although ASV can be differentiated antigenically from the other human polyomaviruses (BK and JC viruses), it shares 94.9% homology at the nucleotide level with the Dunlop strain of BK virus. Differences found in ASV relative to BK virus include the absence of tandem repeats in its regulatory region, the deletion of 32 nucleotides in the late mRNA leader region (altering the initiation codon for the agnoprotein), the presence of a cluster of base pair substitutions within the coding region of the major capsid protein, VP1, and the absence of 4 amino acids in the carboxy-terminal region of the early protein, T antigen. The 43 nucleotides deleted in the Dunlop strain of BK virus relative to the Gardner prototype strain of BK virus are present in ASV. Possible reasons for the distinct antigenicity of the ASV capsid, given the high degree of nucleotide homology with BK virus, are discussed. To reflect the high degree of sequence homology between ASV and BK virus, we suggest ASV be renamed BKV(AS).
The first polyomaviruses discovered in humans, BK virus (BKV) and JC virus (JCV), were isolated in 1971 from urine (13) and brain tissue (36) , respectively. Subsequently, a number of BKV and JCV variants have been recovered from their human hosts and characterized. In 1980, Coleman and co-workers (7) identified a polyomavirus in the urine of a pregnant woman (initials AS) that replicated in human fetal kidney, lung, and glial cells. Although it exhibited the same host range that BKV did, this new virus did not react with antisera raised against intact BKV virions and was therefore designated AS virus (ASV). In 1983, Gibson and Gardner (14) examined the restriction enzyme patterns and antigenic characteristics of ASV. Unique BamHI and HindIIl restriction profiles were observed, but overall the restriction patterns of ASV DNA were similar to those of BKV DNA. When the antigenic properties of the ASV capsid were analyzed with type-specific rabbit antisera raised against BKV or JCV virions, only a very weak cross-reaction was detected between BKV and ASV; no cross-reaction was observed between JCV and ASV. A sero-epidemiological study of 350 people demonstrated that 40 to 50% of the adult English population possess antibodies to ASV and that seroconversion generally occurs between the ages of 10 and 20 (14) . Initial BKV infections generally occur at a younger age and in a higher percentage (70 to 80%) of the people (12) . Gibson and Gardner (14) concluded from this data that ASV was a new human polyomavirus and that it was more closely related to BKV than to JCV.
Because ASV remains an incompletely characterized human virus that is endemic in the population, we have determined its nucleic acid sequence. This information has allowed us to analyze the genetic organization of the viral genome and to study its evolutionary relationships with BKV and JCV. The restriction fragment sizes determined by Gibson and Gardner (14) are confirmed by sequence data, and the cloned ASV possesses the same serological reactivity and lytic activity as the original isolate, indicating that the * Corresponding author.
sequenced ASV strain is the same as the one originally studied by these investigators.
The sequence of ASV reveals a remarkable similarity to that of the Dunlop strain of BKV [BKV(DUN); 44] ; the two viruses are 94.9% homologous at the nucleotide level. Although ASV and BKV(DUN) differ considerably in their noncoding regulatory regions, the organization of the ASV regulatory signals is similar to that found in some BKV variants. Differences between the ASV and BKV(DUN) DNAs are also apparent within those sequences encoding the carboxy terminus of T antigen and the amino terminus of the agnoprotein. Overall, the similarity of ASV and BKV(DUN) at the sequence level is in contrast to the variance previously reported for their restriction patterns and antigenic properties. The sequence analysis of ASV indicates that it is not a new human polyomavirus but an antigenic variant of BKV.
MATERIALS AND METHODS
Viruses and plasmids. The passage history of ASV has included propagation in primary human fetal glial cells (2 passes), human embryonic kidney cells (3 passes), and human embryonic lung cells (9 passes). The virus was present originally in the primary human fetal glial and human embryonic kidney cells as a mixed infection with JCV (14) . Only JCV was expressed in these cells, and it was not until the mixture was passaged in human embryonic lung cells that JCV expression was replaced by that of ASV. Separation from JCV was achieved by a series of terminal dilutions of the viruses in human embryonic lung cells (14) . DNA was isolated from this preparation of virions, cut at the unique EcoRI site in the late coding region, and cloned into pBR322. To ensure that these DNAs represented viable virus, viral sequences were removed from the plasmid, recircularized, and transfected into WI-38 cells (a human diploid cell line established from human embryonic lung cells) by the modified DEAE-dextran transfection method (47) . Transfected cells were inspected for the presence of nuclear viral T antigen by indirect immunofluorescence (5) and for cyto-pathic effect (34) . The production of infectious virions was confirmed by passage of extracts of the transfected cells onto additional WI-38 cells and looking for the appearance of viral T antigen, cytopathic effect, and ASV DNA (determined by restriction enzyme digests of low-molecular-weight DNA) (19) . One clone, pASV2, was chosen for further analysis. Restriction endonuclease patterns, serological reactivity, and lytic activity all indicate that pASV2 is a representative clone of the original ASV population. Viral sequences were excised from pBR322 and ligated into the EcoRI site of the plasmid sequencing vector Bluescript-minus, KS polylinker (BSMKS; Stratagene Cloning Systems) to generate the plasmid pASV2-BSMKS.
Unidirectional deletions. To produce subclones of pASV2-BSMKS for sequencing, unidirectional deletions were generated by the method of Henikoff (18) as adapted by the Erase-a-Base system (Promega Biotec) and further modified in our hands. Briefly, 15 ,ug of pASV2-BSMKS was cut to completion with ApaI and ClaI (New England BioLabs, Inc.) and treated with 500 U of exonuclease III (Exo III; Stratagene Cloning Systems). Aliquots containing 0.6 ,ug of pASV2-BSMKS were removed from the Exo III digestion at 30-s intervals and placed on dry ice. Because ApaI generates a 3' overhang that is resistant to Exo III digestion, adjacent plasmid sequences (including the sequencing primer sites) were protected and digestion proceeded only from the susceptible 5' overhang generated by ClaI. Progressively longer single-stranded regions were generated with increasing Exo III digestion times. These were removed by digestion with 1.6 U of S1 nuclease (Pharmacia Fine Chemicals) per time point. The partially deleted plasmids were purified, and their ends were filled in by using Klenow fragment and deoxynucleoside triphosphates. Plasmids were recircularized and used to transform Escherichia coli NM522 cells.
Plasmid DNA was isolated from bacterial colonies by rapid alkaline extraction (2) and screened for deletions of appropriate sizes by restriction enzyme digests.
Template preparation and sequencing. Double-stranded plasmid templates for sequencing were generated by a modification of the rapid alkaline extraction procedure (2). The double-stranded template sequencing protocol was based on that of Chen and Seeburg (4) as modified by New England BioLabs; [ot-32P]dATP was used to radiolabel the extension products. The entire sequence was determined at least twice, and 95% of the sequence was determined for both strands. Sections not determined on both strands by the enzymatic method were confirmed by the chemical degradation method of Maxam and Gilbert (31) .
DNA sequence analysis. Sequence data was compiled by using an IBM Personal Computer XT coupled with the International Biotechnologies, Inc., Gel Reader. Analysis software was the IBI DNA/Protein Sequence Analysis System by J. Pustell. Hydropathy indexes were generated by the software by using the scale of Kyte and Doolittle (26) . The hydropathy index is a measure of the average hydrophobicity in the center of a sliding window 9 amino acids (aa) in length. It is a dimensionless value ranging from -4 (very hydrophilic) to 4 (very hydrophobic), with neutral hydrophobicity at -0. 4 (52) . After transfection, cultures were maintained in Dulbecco modified Eagle medium with 5% fetal bovine serum and medium was changed every 4 to 5 days. Cells were fixed with 3.7% formaldehyde and stained with hematoxylin at 30 to 38 days posttransfection to facilitate enumeration of dense foci. Cells from three independent foci were isolated and cloned by limited dilution for each DNA used in experiment 2 (see Table 2 ). These cells exhibited a transformed morphology and expressed nuclear T antigen.
Immunological methods. Hemagglutination (HA) and hemagglutination inhibition (HAI) titers were determined as described previously (35) , except that a microdilution technique was employed (46) . The highest dilution of virus suspension that showed complete hemagglutination was considered to contain 1 HA unit (HAU) of virus. Antibodies were produced by injecting adult female New Zealand white rabbits intravenously with ASV, BKV, or JCV. Animals received a single injection and were bled 10 days later. Human sera were obtained from R. Golubjatnikov, Immunology Section, Wisconsin State Laboratory of Hygiene. All sera were heated at 56°C for 30 min and treated with NaIO4 before being tested for HAI antibodies (35) . An HAI titer of 32 or greater was considered a positive indicator of prior infection by the virus. The nucleotide sequence of ASV reveals an unexpectedly high degree of homology (94.9%) with that of BKV(DUN) (44) , given that previous immunological and restriction enzyme analyses by Gibson and Gardner (14) had indicated only a weak relationship between ASV and the prototype BKV. The genetic organization of ASV is essentially identical to that of SV40, BKV, and JCV; open reading frames for two early (T, t) and four late (VP1, VP2, VP3, and agnoprotein) proteins are predicted from the sequence data. GCTTCTGEj TTTTGGGGGT GGTGTTTTAG GCCTTTTAAA   2620  260   2660  2680  2700  ACACTGAAAG CCTTTACACA AATGTAACTC TTGGCTGTGA GGGTTTTCTG AATCAGGGGC TGAAGTATCT GAGACTTGGG AAGAGCATTG TGATTGGGAT   2720  2740  2760  2780   2800   TCAGTGCTTG ATCCATGTCC AGAGTCTTCA GTTTCTGAAT CTTCTTCTCT TGTAATATCA AGAATACATT TTCCCATGCA TATATTATAT TTCATCCTTG   2820  2840  2860  280  2900   AAAAAGTATA CATACTTATC TCAGAATCCA GCCTTTCCTT CCATTCAACA ATTCTAGACT GTATATCTTT TGAAAAATCA GCTACAGGCC TAAACCAAAT   2920  2940  2960  2980  3000  TAGTAGTAGC AAAAGGGTCA TTCCACTTTG TAATATTCTT TTTTCAAGTA AAAACTCAGA GTTTTGCAGG GACTTTCTTA AATATATTTT GGGTCTAAAA   3020  3040  3060  3080  3100  TCTATCTGTC TTACAAATCT Within these blocks, NF-BK sites (1z), AP1 sites (A), Li sites (_), and Spl sites (+-) (left-pointing arrow indicates CCCGCC polarity, right-pointing arrow indicates opposite polarity) are indicated. ?, Spl sites determined solely by similarity to the consensus sequence; *, NF-BK sites formed by sequences unique to BKV9 and determined by similarity to the consensus sequence; A\, position of a 32-bp deletion relative to the other viruses. Numbers above the linear arrangement refer to the sizes (in base pairs) of the indicated structures; numbers below refer to the distances between structures.
found in BKV(DUN) (55) . As the entire BKV(WT) sequence has not been published, the BKV(WT) numbering system used here begins in the center of the origin of replication and proceeds towards the late coding region [as for BKV(DUN)] and assumes that there are no insertions or deletions in BKV(WT) relative to BKV(DUN) outside of the regulatory region. The ASV regulatory region shows a number of distinct alterations from that of BKV(WT), especially to the late side of the origin of replication. These changes are shown schematically in Fig. 2 . The changes discussed below use the terms insertion and deletion with respect to BKV(WT), but they are used for convenience only and are not meant to imply any direct evolutionary descent of ASV from BKV(WT). In all probability the two viruses are derived from a common ancestor and not from each other. Specific minor changes found in ASV relative to BKV(WT) were an extra A in the poly(A) stretch from 4996 A block homologous to the 63-bp insertion has been observed before in the BKV variants BKV(Dik) (49), BKV(WW) (42) , and BKV(R2) (38) . The early 34 bp of the 63-bp block are found in BKV(JL) (49) , and the late 47 bp of this block are found in BKV(IR) (37) . In none of these cases is the 63-bp block identical to the ASV block. ASV 146 is a C, but the corresponding nucleotide is an A in BKV(Dik), BKV(WW), BKV(R2), and BKV(JL) [ 11 (25) 29 (26) 31 (24) pBKV9 163 (17) 127 (18) 172 (14) pBKV9 (d1143) 126 (16) a Rat 2 cells were transfected with 1.0 ,ug of each DNA by using the calcium phosphate coprecipitation technique (52) . ASV and BKV DNAs were cloned into pBR322 at their unique EcoRI sites. transforming ability, BKV9(dll43) was included in the third experiment. BKV9(dll43) is a deletion mutant of BKV9 that contains only one copy of the 143-bp duplication. Watanabe and Yoshiike (51) and Hara et al. (17) have shown that reducing the number of 68-bp repeats in BKV(WT) increases its transforming ability. BKV9(d1143), however, showed reduced transforming activity relative to BKV9, and the foci that formed were smaller and more compact.
Immunological characteristics. The immunological reactivity of ASV, BKV, and JCV virions to antibodies generated against all three viruses is listed in Table 3 . Four antisera were used, two generated against the pool of ASV from which the clone pASV-2 was made, one against BKV(WT), and one against JCV (Mad-1 strain). HAI titers of these sera were determined by using 8 HAU of each of the viruses used to immunize the rabbits. These sera were also tested against ASV virions [ASV(cloned)] that were produced from cells transfected with pASV-2 (viral DNA removed from plasmid). The HAI titers of the four antisera were essentially identical when ASV(cloned) or the parental ASV was used as the hemagglutinating agent. Antibodies raised against BKV did not cross-react with ASV, as was found in earlier studies (7, 14) . However, antibodies raised against ASV reacted equally well with BKV and ASV, in contrast to earlier studies (14) , in which only a weak cross-reaction was seen between BKV and ASV by using antisera obtained 1 month postinoculation. In no case was a significant crossreaction seen between JCV and either ASV or BKV.
From these data, it appears that ASV lacks the primary antigenic epitope(s) recognized on the BKV virion but (7, 14) and from which the recombinant DNA clone was produced.
c HAI titers are the inverse of the greatest dilution of antibody that inhibits agglutination of human erythrocytes by 8 HAU of virus. (7) . Analysis by HAI and by restriction enzyme digestion (14) suggested that ASV was a new strain of human polyomavirus that was more closely related to BKV than to JCV. Serological studies indicated that ASV is endemic in the population, since 40 to 50% of the adults in England possess antibodies to the virus (14) . Because ASV is incompletely characterized and is widespread in the population, we decided to define its relationship to the better-known human polyomaviruses. As a first step in the analysis, the entire ASV genome was cloned and sequenced. ASV was found to be surprisingly similar to BKV(DUN); these viruses share a homology of 94.9% at the nucleotide level.
The largest differences between ASV and BKV are found in the noncoding regulatory region. The ASV region differs considerably from those of BKV(DUN) and BKV(WT) but is similar to the regulatory regions of the BKV variants BKV(Dik) and BKV(WW) (42, 49) . The arrangement of the ASV regulatory blocks is also similar to that of the evolu-VOL. 63, 1989 on October 19, 2017 by guest http://jvi.asm.org/ Downloaded from tionary prototype, or archetype BKV, proposed by Yoshiike and Takemoto (42, 56) . From the early to the late side of the regulatory region, the archetype contains a palindrome, two inverted repeats, an AT-rich region, a 68-bp block, a 39-bp block, a 63-bp block, and a putative leader region for the late message (the region is shown graphically in Fig. 2 detected by these investigators. NF-BK is a member of the nuclear factor I family (9); it is provisionally referred to as NF-BK until its relationship to other members of the family can be determined. The consensus NF-BK binding site is TGGAA(T/A)(G/C)(C/T)(A/T)GCCAAA (30) . The transcriptional activator Spl binds the consensus sequence (G/T) (GIA)GGCG(GtT)(GIA)(GIA)(CIT) (15) . AP1 binds to the sequence TGACTCA (27) . Potential AP1 binding sites were not identified from ASV sequence information, although sites are predicted in BKV(WT). ASV does not contain the Li site (it was located in the 32 bp lost from the late-leader region); therefore, binding to Li is not essential for viral growth. The Li binding site is found in BKV(WT).
Deyerle and co-workers (8) recently analyzed the BKV(WT) early promoter and enhancer. By their analysis, the minimal BKV early promoter is composed of the sequences PAL-IR-IR-TATA plus the early portion of the first 68-bp block. ASV contains the same arrangement, and these sequences probably form the ASV early promoter. Deyerle and co-workers found that the optimal BKV(WT) enhancer consists of two 68-bp blocks and an element termed C (located in the 39-bp block, overlapping an NF-BK site). The ASV regulatory region contains one copy of the 68-bp block plus the C element; it also contains a 63-bp block. The 63-bp block in ASV might substitute for a 68-bp block of BKV(WT) to yield full ASV enhancer activity.
A deletion mutant of BKV(WT) containing only one 68-bp block (d1504, PAL-IR-IR-TATA-68-C-LL) demonstrates an increased transforming ability (17, 51) . ASV contains only one copy of the 68-bp block, yet a significant difference in the transforming abilities of ASV and BKV(WT) was not observed. If the 63-bp element can substitute for a 68-bp element, ASV would resemble the BKV(WT) deletion mutant d1503 (PAL-IR-IR-TATA-68-68-C-LL). d1503, like BKV(WT), transforms cells inefficiently (51) . BKV9 contains a tandem duplication of 143 bp in the enhancer region, yet it transforms efficiently. Inspection of the BKV9 regulatory region shows that, although it includes approximately the same number of potentially active transcription signals as does BKV(WT) (Fig. 2) , they are arranged in two groups separated by a short length of the late coding region. This novel arrangement may alter the interaction of potential regulatory proteins that bind to these sites. The cumulative effects of this arrangement are unknown, but they may be sufficient to produce an elevated transforming activity similar to that found in d1504 (51) . The regulatory region of BKV9(d1143) is nearly identical to that of d1504; this virus also transforms Rat 2 cells efficiently.
The transforming T antigens of ASV and BKV(DUN) are nearly identical, but the extreme carboxy-terminal region of the-ASV T antigen lacks 4 aa found in the corresponding region of the BKV(DUN) T antigen [BKV(DUN) aa 664-665 deleted and aa 668-671 deleted and replaced by Glu-Asn]. Alterations to the analogous sequences of SV40 T antigen (aa 675 to 681) lead to reduced virus yields and cold sensitivity for growth in the CV1-P and BSC cell lines (6, 39) . The adenovirus helper function of SV40 T antigen has been mapped to aa 674 to 699 (6) , and this function in SV40 may contribute to posttranscriptional regulation of the agnoprotein (21) . When grown in CV1-P or BSC cells, mutant viruses lacking SV40 T antigen aa 671 to 708 (d11066) or aa 676 to 685 (d11140) express the late mRNAs and the late structural proteins at a 5-to 15-fold lower level than does wild-type virus, but they express the agnoprotein at a level that is 100-fold lower. If an analogous posttranscriptional mechanism operates in ASV and BKV(DUN), the deletions in ASV in the T antigen and in the late-leader region upstream of the agnogene could disrupt this mechanism and alter the levels of agnoprotein produced in infection.
The deletion of 32 bp in the late-leader region of ASV alters the agnogene initiation codon and shifts a potential replacement initiation codon 24 bp upstream. If this alternate ATG is functional, the proposed agnoprotein would be increased in size from 66 aa in BKV(DUN) to 74 aa in ASV. Changes to the coding sequence would be limited to the addition of the sequence Met-Phe-Cys-Glu-Pro-Lys-AsnLeu at the amino terminus and replacement of the original amino-terminal methionine with an internal valine. Another difference between the ASV and BKV(DUN) agnoproteins might be their levels of expression; the translational efficiency of the new start site may differ from that of the original site. It is also possible that alteration of the start site prevents synthesis of the ASV agnoprotein or yields a nonfunctional protein. This would not necessarily be inconsistent with the finding that ASV is viable, since the SV40 agnoprotein has been shown to be nonessential for growth in vitro (32, 48) . Resnick and Shenk (41) have shown that mutating the SV40 agnogene ATG initiation codon to TTG (pm1493, SV40 335 A to T) prevents agnoprotein synthesis, yet the mutant virus is viable in tissue culture.
DNA sequence homology data support the suggestion that the alternate ATG of the ASV agnoprotein is functional and that this protein is expressed. Beyond the amino-terminal sequences, the ASV and BKV(DUN) agnoprotein sequences have been conserved; there are no insertions or deletions within this 225-bp gene, indicating that it has been maintained through selective pressure in vivo. In contrast, all of the predicted noncoding regions in ASV contain insertions or deletions when compared to BKV(DUN). Inspection of the sequences surrounding the putative ASV agnogene initiation codon yields additional evidence that this signal is utilized. The consensus flanking sequence for eucaryotic mRNA initiation codons is CC(A/G)CCAUGG (22, 23) . The flanking sequence for the BKV(DUN) agnogene initiation codon is AGGCCAUGG; for the putative ASV agnogene initiation codon it is CAGACAAUIT. Kozak (22) inspected 211 mRNA leader sequences and found that a purine was present at position -3 (A of AUG is +1) in 97% of these messages. Although A is favored in the -3 position, G is frequently found. Because the late mRNAs that code for the agnoprotein are polycistronic, it may be necessary that the consensus flanking sequences of the BKV(DUN) and ASV agnogene start sites be imperfect. The agnoprotein message is located within the common 5' domain of the late mRNA and hence is present in both the 19S VP2 and VP3 and in the 16S VP1 mRNAs. Flanking sequences of the initiation codons affect the relative levels of synthesis from the various open reading frames in a polycistronic eucaryotic mRNA (24, 25) . Thus, the nearly equivalent initiation flanking sequences for the ASV and BKV(DUN) agnogenes may indicate a similar level of coordination of late protein translation in the two viruses.
The distinct antigenicity of ASV is intriguing given the high degree of homology between the structural proteins of ASV and BKV(DUN). A possible explanation for the differing immunogenicity of these two viruses is based on the 38-aa differences in their late structural proteins. These amino acid changes produce two noticeable differences in the hydrophobicity profiles of the ASV and BKV(DUN) VP1 proteins; one of these differences represents a distinct cluster of altered amino acid residues in the amino portion of VP1. It is possible that the point mutations have removed the epitopes recognized on the BKV virion, leaving only weaker epitopes that are not normally recognized in BKV to be recognized on the ASV virion. As these weaker epitopes are found on the BKV virion, the antibodies generated by ASV would also react with BKV.
An alternative explanation for the distinct antigenicity of ASV involves the interaction of VP1 with the agnoprotein. The function of the agnoprotein in polyomaviruses is not well understood, but a number of activities have been ascribed to the SV40 protein. The SV40 agnoprotein participates in virion production after the removal of DNA from the replication pathway (20) ; it binds VP1 in infected cells and helps to temporally regulate the nuclear localization of VP1 (3). In cells infected with agnogene deletion mutants, virion burst size is decreased 17-to 100-fold (33, 41) , but the kinetic pattern of VP1 polymerization is unchanged; it remains cooperative (33) . An activity of agnoprotein may also be involved in host cell lysis (41) . The SV40 agnoprotein may act by inhibiting VP1 polymerization until the latter protein can productively encapsidate minichromosomes in the nucleus (1). On the basis of the activities of the SV40 agnoprotein, a number of possibilities can be proposed to explain how the altered ASV agnoprotein might affect the antigenicity of the capsid. While bound to VP1 in the cytoplasm, the altered amino terminus of the ASV agnoprotein may affect the posttranslational modification of the major capsid protein and hence modify an epitope. Alternatively, the ASV agnoprotein may affect the polymerization pattern of VP1 through its interaction with this protein in the cytoplasm and nucleus. In mouse polyomavirus, purified VP1 can polymerize in vitro into a number of capsidlike structures (43) and hence may alter the availability of different antigenic epitopes to be recognized. These possibilities for the generation of altered antigenicity of ASV relative to BKV need not be independent or exhaustive.
A scheme for the divergence of ASV from the archetype BKV can be proposed that rests on two assumptions: (i) an ASV agnoprotein is produced which functions in a manner that is similar to that of its SV40 counterpart, and (ii) posttranscriptional regulation of expression of the human polyomavirus agnoproteins occurs via T antigen. The initial event in the divergence of ASV from the archetype might have been the deletion of sequences from the late-leader region, thereby altering the agnogene product and disrupting its normal regulation by T antigen. Secondary events would then have involved the alteration of the T antigen and VP1 coding sequences to adapt to this primary mutation. Deletion of sequences in the carboxy-terminal domain of T antigen might have allowed ASV to reestablish proper regulation of the translation of the agnogene. The occurrence of a number of point mutations within the VP1 coding region may have been important to the maintenance of a productive interaction between VP1 and agnoprotein (second-site revertants are found in SV40 in the agnoprotein when VP1 is mutated [29] and in VP1 when the agnoprotein is mutated The sequence data presented here indicate that ASV is not a distinct human polyomavirus but rather an antigenic variant of BKV. We therefore suggest that its name be changed from ASV to BKV(AS) to better reflect this relationship.
